Medicare GLP-1 Coverage 2026 Houston: Ozempic, Wegovy, Mounjaro Costs and What Changes January 2027

Picture this: a Tuesday morning in Bellaire, the coffee going cold, and three things on the kitchen table at once. A brand-new 2026 Medicare Part D card. A prescription your doctor wrote yesterday for Wegovy after a serious conversation about your heart. And a printed quote from the H-E-B pharmacy on Bissonnet that reads $1,300 for a 28-day pen. The TV said Medicare was finally negotiating prices on Ozempic and Wegovy. Your neighbor in Spring Branch said her plan covers Ozempic for diabetes. A cousin in The Woodlands said the negotiated price kicks in — but no one is sure when. That is the conversation Wise Insurance Agency walks Houston seniors through every week in 2026, and it always starts with: is this drug covered for me, today, on my plan?

This guide answers that question. We cover what Medicare Part D actually covers in 2026 for GLP-1 drugs — Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus — the statutory rule that excludes weight-loss prescribing, the 2024 cardiovascular exception, the new $2,100 Part D out-of-pocket cap, and what changes on January 1, 2027 when Medicare-negotiated prices on semaglutide products take effect. Every number is sourced. When you are ready to look at your own plan, your own prescription, and your own pharmacy, call 832-743-1318 — that is what we do at the kitchen table.

Why GLP-1 drugs are the biggest Medicare conversation in 2026

Walk into a Wise Insurance Agency appointment in 2026 and you can predict the questions. Half of all new Medicare consultations in Harris County now mention a GLP-1 by name. Ozempic. Wegovy. Mounjaro. Zepbound. Rybelsus. The reasons are not mysterious. Adult diabetes prevalence in Harris County sits near 12% per CDC PLACES, and adult obesity prevalence near 35% — both above Texas and US averages. Cardiovascular disease is the leading cause of death in Harris County — exactly the patient population Wegovy’s 2024 cardiovascular indication targets.

The Medicare math has not caught up to the cultural moment. A GLP-1 prescription written for the wrong indication on the wrong plan can cost $13,000 a year out of pocket in Houston in 2026. The same drug written for a covered indication on a plan with smart tier placement can cost $2,100 in total for the year — because of the new Part D cap. That is a six-fold difference for the same molecule. The KFF Part D issue brief walks through the structural pieces; what KFF cannot do is sit at your kitchen table in Cypress or Pasadena and read your specific 2026 formulary against the prescription your cardiologist just wrote.

Coverage is not a property of the drug. It is the intersection of the drug, the indication, your plan’s formulary, the prior authorization criteria, the step therapy rules, your pharmacy, and where you sit on the 2026 Part D benefit curve. Wise Insurance Agency compresses that intersection into a single answer for the senior across the table — whether you live in Sugar Land, the Heights, or The Woodlands.

What Medicare Part D actually covers — and what it doesn’t

Start with the rule that confuses Houston Medicare beneficiaries more than any other: Medicare Part D never covers a drug when it is prescribed for weight loss. Not a plan-level choice. Not a formulary decision. Federal law, codified at 42 USC §1395w-102(e)(2)(A), which lists drugs Part D plans cannot cover — and “agents when used for anorexia, weight loss, or weight gain” is on the list. Every Part D plan in every state is bound by it. No richer plan can buy around it because no plan is allowed to offer it.

The same drug, however, can be covered when prescribed for a different indication. Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus. Ozempic and Rybelsus are FDA-approved for Type 2 diabetes; Wegovy is FDA-approved for chronic weight management and (since 2024) for reducing major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Diabetes is covered; weight management is not; the cardiovascular indication is covered when documented properly. The molecule is identical. The indication on the prescription determines coverage. That is the single most-missed point in the kitchen-table conversation.

Inside the diabetes pathway, every Houston Part D plan in 2026 covers at least one GLP-1 — usually Ozempic, Trulicity, or Mounjaro — but on different tiers with different prior authorization rules. PA criteria often require documented A1C readings and a metformin trial, paperwork your endocrinologist’s office handles but that can delay your first fill by one to three weeks if it stalls.

The Wegovy cardiovascular exception (CMS March 2024 guidance)

For years the answer to “does Medicare cover Wegovy” was a flat no. That changed in March 2024, when the FDA approved a new indication for semaglutide 2.4 mg (Wegovy): reducing the risk of major adverse cardiovascular events — CV death, non-fatal MI, non-fatal stroke — in adults with established cardiovascular disease and either overweight or obesity. The supporting trial, SELECT, published in the New England Journal of Medicine in late 2023, showed a 20% reduction in MACE on semaglutide 2.4 mg versus placebo.

Shortly after the FDA approval, CMS issued HPMS guidance to Part D plan sponsors clarifying that Wegovy is permitted on Part D formularies when prescribed for the cardiovascular indication, because that indication is not “weight loss” within the statutory exclusion. The guidance opened a pathway; it did not require plans to use it. Many did, starting with 2025 plan offerings and continuing into 2026, generally on tier 4 or specialty tier.

At the kitchen table in The Woodlands or Sugar Land, this means a Houston senior with documented established cardiovascular disease — prior heart attack, stroke, peripheral artery disease, or symptomatic CAD — plus a BMI of 27 or higher may have a Part D pathway to Wegovy that did not exist before 2024. Three pieces must line up: cardiology office documents the indication, prior authorization is submitted with qualifying CV history, and the plan covers Wegovy on its formulary.

Mounjaro and Zepbound — what’s different about tirzepatide

Tirzepatide is the active ingredient in two Eli Lilly products: Mounjaro (Type 2 diabetes) and Zepbound (originally chronic weight management, with a December 2024 FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity). Same molecule, different brand, different indication — and the same Medicare puzzle as semaglutide.

Mounjaro is widely on Houston Part D formularies in 2026 when prescribed for Type 2 diabetes, typically on tier 4 or specialty tier with prior authorization. Many plans use step therapy requiring metformin plus a second oral agent first. The clinical evidence is strong — the SURPASS trial program showed A1C reductions and weight loss superior to semaglutide head-to-head — and Houston endocrinologists prescribe tirzepatide frequently.

Zepbound is the harder case. Weight management runs straight into the statutory exclusion. The December 2024 sleep apnea indication opens a narrower Part D pathway in 2026 — analogous to Wegovy’s CV pathway but earlier in its rollout. It requires documented OSA (sleep study), documented BMI, and a plan that adds Zepbound to its formulary for the OSA indication. Houston-area Part D plan adoption for OSA is uneven in 2026.

The $2,100 Part D out-of-pocket cap in 2026 — how it changes GLP-1 math

The single most important number in this guide is $2,100 — the 2026 annual out-of-pocket maximum for covered Medicare Part D drugs, adjusted by CMS from the 2025 statutory floor of $2,000 by the Part D annual cost growth factor under the IRA. The cap is structural. It applies to every standalone Part D plan and every MA-PD plan sold in Houston in 2026. Once your true out-of-pocket spending on covered Part D drugs reaches $2,100, you pay $0 for the rest of the calendar year on covered prescriptions.

For a Houston senior on a covered GLP-1, the cap is the entire game. Before 2025, a Wegovy or Ozempic prescription could push annual out-of-pocket spending well above $5,000 on plans with specialty-tier coinsurance. In 2026, the math stops at $2,100, no matter how expensive the drug or how many drugs you take. The cap is shared across all Part D drugs — if you also take Eliquis and Imbruvica, you reach $2,100 even faster, and the rest of the year is $0.

The Medicare Prescription Payment Plan, available in 2025 and continuing in 2026, does not change what you pay annually — you still pay up to $2,100 — but it spreads that cost across even monthly installments instead of a $1,500 January hit at the H-E-B pharmacy when you start a GLP-1. The plan administers it; you enroll once and it applies to every covered fill.

What January 1, 2027 actually brings (Round 2 negotiated prices)

Headlines collapse this into a sentence. The accurate version: CMS announced the second round of selected drugs for Medicare price negotiation in January 2025, and the negotiated Maximum Fair Prices take effect on January 1, 2027 — not in 2026. The selection includes semaglutide products (Ozempic, Wegovy, Rybelsus) as one negotiated unit because they share an active ingredient. See the CMS Medicare Drug Price Negotiation Program page.

The 2027 MFP will not appear at the pharmacy counter in 2026. Your January 2026 Wegovy fill reflects the 2026 plan-negotiated price applied against your tier and the $2,100 cap. Your January 2027 fill — assuming you stay on the drug and on a plan that covers it — will reflect the MFP, expected to be a substantial discount to the 2026 net price. The exact semaglutide MFP will be published by CMS during 2026.

The MFP is what Medicare and Part D plans pay the manufacturer. It is not what the beneficiary pays at the counter. You still pay cost-sharing — deductible, coinsurance — until reaching the annual cap. The MFP lowers the underlying drug cost; the plan’s tier and coinsurance design determine how much flows through to your wallet. In practice, most Houston seniors will see a faster path to the annual cap and slightly lower per-fill cost-sharing on the way there.

Prior authorization, step therapy, and Houston Part D formularies

Coverage in the abstract is not coverage at the pharmacy counter. The bridge is paperwork — prior authorization (PA) and step therapy. Every Houston Part D plan in 2026 uses both on GLP-1 drugs, with criteria that vary by plan.

Prior authorization requires your prescriber to submit clinical documentation supporting the indication before the plan pays. For Ozempic and Mounjaro on the diabetes pathway, typical PA criteria require a Type 2 diabetes diagnosis (ICD-10 codes), recent A1C results, and a documented trial of metformin or contraindication. For Wegovy on the cardiovascular pathway, PA documentation typically requires established CV disease (prior MI, stroke, peripheral artery disease, or symptomatic CAD), BMI of 27 or higher, and the cardiologist’s attestation that the prescription is for MACE reduction.

Step therapy requires trying lower-cost or preferred alternatives first. Many Houston plans require documented metformin trials before authorizing a GLP-1 for diabetes. Step therapy can delay your first fill by weeks, but the rules are negotiable when documented contraindications exist — your endocrinologist’s office pushes the appeal.

Our Medicare Plans overview and Medicare Advantage page connect to the GLP-1 conversation. If you are choosing between an MA-PD plan and a Medigap policy with a standalone Part D plan (see Medicare Supplement Plan), your GLP-1 prescription becomes a deciding factor — the plan with the smoothest PA pathway for your prescriber’s preferred drug is the right plan, even at a slightly higher premium.

Houston-specific costs: pharmacy quotes from Bellaire to The Woodlands

Pharmacy choice matters less than plan choice in 2026 but still matters at the margins. Part D plans contract with preferred pharmacy networks, and cost-sharing on tier 4 or specialty-tier GLP-1 drugs is usually lower at a preferred pharmacy than a non-preferred one. The difference is rarely dramatic on GLP-1s — but on a $1,300 fill, the gap between 25% and 33% coinsurance is real money.

H-E-B Pharmacy locations across Bellaire and Bunker Hill are preferred in several Houston-area Part D plans. Kroger Pharmacy across the Heights and Cypress is preferred in others. Walgreens on Westheimer and across Spring Branch and CVS in Pasadena, Sugar Land, and The Woodlands round out the major chains. Independent pharmacies serving Vietnamese, Spanish-speaking, and Chinese-American communities in southwest Houston participate too, usually at standard (not preferred) tier. See our North Houston and South Houston office pages.

Manufacturer savings programs and why Medicare beneficiaries can’t use most of them

If you have visited Novo Nordisk or Eli Lilly websites you have seen savings card offers — “as little as $25 a month” for eligible patients. Medicare beneficiaries are not eligible for those savings cards. Not marketing — federal law. The anti-kickback statute and OIG guidance prohibit manufacturer financial inducements to federal healthcare program beneficiaries, including Medicare Part D enrollees. Manufacturers state this in their terms.

Available to Houston Medicare beneficiaries is the patient assistance program (PAP) from each manufacturer. Novo Nordisk’s PAP and Eli Lilly’s PAP have income and insurance criteria. They are not co-pay cards — they supply the drug at no charge to qualifying low-income patients. For a Medicare beneficiary, qualifying often hinges on whether your Part D plan covers the drug at all (if it does, the PAP usually will not).

What to do at the kitchen table — your 2026 GLP-1 decision tree

This is the conversation we have with Houston seniors every week. Six steps work for nearly everyone.

Step 1: Confirm the indication. What is your prescriber actually writing the prescription for? Type 2 diabetes, established CV disease with overweight/obesity, OSA with obesity, or weight loss alone? The first three have Part D pathways in 2026; the last does not.

Step 2: Pull your Part D plan’s 2026 formulary. Find your specific GLP-1 on the list. If it is not there, your options are: ask the prescriber to switch to a covered alternative, request a formulary exception, or change plans at the next Annual Enrollment Period.

Step 3: Run the math against the $2,100 cap. Add up expected 2026 out-of-pocket spending on all covered Part D drugs. If the total exceeds $2,100, your worst-case 2026 cost is $2,100.

Step 4: Decide on the Medicare Prescription Payment Plan. If January and February fills will be heavy, enrolling in the smoothing plan turns a $1,500 January hit into roughly $175 a month for 12 months.

Step 5: Confirm the prior authorization is submitted. Verify with the prescriber’s office that the PA was filed with the correct indication and supporting documents. Most Houston denials come from incomplete submissions, not genuine ineligibility.

Step 6: Look ahead to 2027. If you start a semaglutide product in 2026, the Round 2 MFP applies January 1, 2027 — your underlying drug cost drops and per-fill cost-sharing may drop with it. Plan selection at the 2026 AEP (October 15 to December 7) should factor in 2027 expectations.